Donanemab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Donanemab. Educational only — not medical advice.
Labeled uses
KISUNLATM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials.
Source: FDA labeling via NIH DailyMed (set 190352d4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.